{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T01:51:46Z","timestamp":1768787506338,"version":"3.49.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100010099","name":"\u00dastav organick\u00e9 chemie a biochemie Akademie v\u011bd \u010cesk\u00e9 republiky","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R21NS118337-01"],"award-info":[{"award-number":["R21NS118337-01"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R21NS084900"],"award-info":[{"award-number":["R21NS084900"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS092786"],"award-info":[{"award-number":["R01NS092786"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s43440-022-00437-1","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T17:33:52Z","timestamp":1669311232000},"page":"177-188","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Novel neurosteroid pregnanolone pyroglutamate suppresses neurotoxicity syndrome induced by tetramethylenedisulfotetramine but is ineffective in a rodent model of infantile spasms"],"prefix":"10.1007","volume":"75","author":[{"given":"Chian-Ru","family":"Chern","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcela","family":"Laukov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Schonwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Kudov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Chodounsk\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chian-Jiang","family":"Chern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Shakarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Vel\u00ed\u0161kov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2805-349X","authenticated-orcid":false,"given":"Libor","family":"Vel\u00ed\u0161ek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,23]]},"reference":[{"key":"437_CR1","first-page":"171","volume":"15","author":"P Sobotka","year":"1973","unstructured":"Sobotka P, \u0160afanda J. Analysis of the epileptogenic action of tetramine. Act Nerv Super (Praha). 1973;15:171\u20132.","journal-title":"Act Nerv Super (Praha)"},{"key":"437_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.taap.2012.08.037","volume":"265","author":"MP Shakarjian","year":"2012","unstructured":"Shakarjian MP, Vel\u00ed\u0161kov\u00e1 J, Stanton PK, et al. Differential antagonism of tetramethylenedisulfotetramine-induced seizures by agents acting at NMDA and GABAA receptors. Toxicol Appl Pharmacol. 2012;265:113\u201321.","journal-title":"Toxicol Appl Pharmacol"},{"key":"437_CR3","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1124\/jpet.111.190579","volume":"341","author":"D Zolkowska","year":"2012","unstructured":"Zolkowska D, Banks CN, Dhir A, et al. Characterization of seizures induced by acute and repeated exposure to tetramethylenedisulfotetramine. J Pharmacol ExpTherap. 2012;341:435\u201346.","journal-title":"J Pharmacol ExpTherap"},{"key":"437_CR4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.neuro.2011.10.008","volume":"33","author":"JM Li","year":"2012","unstructured":"Li JM, Gan J, Zeng TF, et al. Tetramethylenedisulfotetramine intoxication presenting with de novo status epilepticus: a case series. Neurotoxicology. 2012;33:207\u201311.","journal-title":"Neurotoxicology"},{"key":"437_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.neuro.2017.08.009","volume":"63","author":"NC Rice","year":"2017","unstructured":"Rice NC, Rauscher NA, Langston JL, et al. Behavioral intoxication following voluntary oral ingestion of tetramethylenedisulfotetramine: dose-dependent onset, severity, survival, and recovery. Neurotoxicology. 2017;63:21\u201332.","journal-title":"Neurotoxicology"},{"key":"437_CR6","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1186\/1471-2458-14-842","volume":"14","author":"Y Li","year":"2014","unstructured":"Li Y, Gao Y, Yu X, et al. Tetramine poisoning in China: changes over a decade viewed through the media\u2019s eye. BMC Public Health. 2014;14:842.","journal-title":"BMC Public Health"},{"key":"437_CR7","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1513\/pats.201001-003SM","volume":"7","author":"DA Jett","year":"2010","unstructured":"Jett DA, Yeung DT. The CounterACT Research Network: basic mechanisms and practical applications. Proc Am Thoracic Soc. 2010;7:254\u20136.","journal-title":"Proc Am Thoracic Soc"},{"key":"437_CR8","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/j.1476-5381.1975.tb07379.x","volume":"53","author":"NG Bowery","year":"1975","unstructured":"Bowery NG, Brown DA, Collins JF. Tetramethylene disulphotetramine: an inhibitor of gamma-aminobutyric acid induced depolarization of the isolated superior cervical ganglion of the rat. Br J Pharmacol. 1975;53:422\u20134.","journal-title":"Br J Pharmacol"},{"key":"437_CR9","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00204-017-2089-4","volume":"92","author":"B Pressly","year":"2018","unstructured":"Pressly B, Nguyen HM, Wulff H. GABAA receptor subtype selectivity of the proconvulsant rodenticide TETS. Arch Toxicol. 2018;92:833\u201344.","journal-title":"Arch Toxicol"},{"key":"437_CR10","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s00204-020-02728-z","volume":"94","author":"B Pressly","year":"2020","unstructured":"Pressly B, Vasylieva N, Barnych B, et al. Comparison of the toxico kinetics of the convulsants picrotoxinin and tetramethylenedisulfotetramine (TETS) in mice. Arch Toxicol. 2020;94:1995\u20132007.","journal-title":"Arch Toxicol"},{"key":"437_CR11","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.neuro.2019.08.004","volume":"74","author":"MC Moffett","year":"2019","unstructured":"Moffett MC, Rauscher NA, Rice NC, et al. Survey of drug therapies against acute oral tetramethylenedisulfotetramine poisoning in a rat voluntary consumption model. Neurotoxicology. 2019;74:264\u201371.","journal-title":"Neurotoxicology"},{"key":"437_CR12","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.neuro.2015.03.007","volume":"48","author":"MP Shakarjian","year":"2015","unstructured":"Shakarjian MP, Ali MS, Veliskova J, et al. Combined diazepam and MK-801 therapy provides synergistic protection from tetramethylenedisulfotetramine-induced tonic-clonic seizures and lethality in mice. Neurotoxicology. 2015;48:100\u20138.","journal-title":"Neurotoxicology"},{"key":"437_CR13","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.neuropharm.2015.03.035","volume":"95","author":"DA Bruun","year":"2015","unstructured":"Bruun DA, Cao Z, Inceoglu B, et al. Combined treatment with diazepam and allopregnanolone reverses tetramethylenedisulfotetramine (TETS)-induced calcium dysregulation in cultured neurons and protects TETS-intoxicated mice against lethal seizures. Neuropharmacology. 2015;95:332\u201342.","journal-title":"Neuropharmacology"},{"key":"437_CR14","first-page":"1223","volume":"270","author":"TG Kokate","year":"1994","unstructured":"Kokate TG, Svensson BE, Rogawski MA. Anticonvulsant activity of neurosteroids: correlation with gamma- aminobutyric acid-evoked chloride current potentiation. J Pharmacol Exp Ther. 1994;270:1223\u20139.","journal-title":"J Pharmacol Exp Ther"},{"key":"437_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2021.115643","volume":"426","author":"PC Mundy","year":"2021","unstructured":"Mundy PC, Pressly B, Carty DR, et al. The efficacy of gamma-aminobutyric acid type A receptor (GABA AR) subtype-selective positive allosteric modulators in blocking tetramethylenedisulfotetramine (TETS)-induced seizure-like behavior in larval zebrafish with minimal sedation. Toxicol Appl Pharmacol. 2021;426: 115643.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"Suppl 2","key":"437_CR16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/epi.13999","volume":"59","author":"D Zolkowska","year":"2018","unstructured":"Zolkowska D, Wu CY, Rogawski MA. Intramuscular allopregnanolone and ganaxolone in a mouse model of treatment-resistant status epilepticus. Epilepsia. 2018;59(Suppl 2):220\u20137.","journal-title":"Epilepsia"},{"key":"437_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0920-1211(00)00170-4","volume":"42","author":"JF Kerrigan","year":"2000","unstructured":"Kerrigan JF, Shields WD, Nelson TY, et al. Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial. Epilepsy Res. 2000;42:133\u20139.","journal-title":"Epilepsy Res"},{"key":"437_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0074-7742(02)49003-4","volume":"49","author":"O Dulac","year":"2002","unstructured":"Dulac O, Soufflet C, Chiron C, et al. What is West syndrome? Int Rev Neurobiol. 2002;49:1\u201322.","journal-title":"Int Rev Neurobiol"},{"key":"437_CR19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.spen.2016.05.004","volume":"23","author":"LR Shao","year":"2016","unstructured":"Shao LR, Stafstrom CE. Pediatric epileptic encephalopathies: pathophysiology and animal models. Semin Pediatr Neurol. 2016;23:98\u2013107.","journal-title":"Semin Pediatr Neurol"},{"key":"437_CR20","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S2352-4642(18)30244-X","volume":"2","author":"FJK O'Callaghan","year":"2018","unstructured":"O\u2019Callaghan FJK, Edwards SW, Alber FD, et al. Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomised controlled trial. Lancet Child Adolesc Health. 2018;2:715\u201325.","journal-title":"Lancet Child Adolesc Health"},{"key":"437_CR21","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/S1474-4422(05)70199-X","volume":"4","author":"AL Lux","year":"2005","unstructured":"Lux AL, Edwards SW, Hancock E, et al. The United Kingdom infantile spasms study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurol. 2005;4:712\u20137.","journal-title":"Lancet Neurol"},{"key":"437_CR22","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1136\/adc.55.9.664","volume":"55","author":"R Riikonen","year":"1980","unstructured":"Riikonen R, Donner M. ACTH therapy in infantile spasms: side effects. Arch Dis Child. 1980;55:664\u201372.","journal-title":"Arch Dis Child"},{"key":"437_CR23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0887-8994(00)00218-6","volume":"23","author":"RS Riikonen","year":"2000","unstructured":"Riikonen RS. Steroids or vigabatrin in the treatment of infantile spasms? Pediatr Neurol. 2000;23:403\u20138.","journal-title":"Pediatr Neurol"},{"key":"437_CR24","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1177\/0883073811413129","volume":"26","author":"CE Stafstrom","year":"2011","unstructured":"Stafstrom CE, Arnason BG, Baram TZ, et al. Treatment of infantile spasms: emerging insights from clinical and basic science perspectives. J Child Neurol. 2011;26:1411\u201321.","journal-title":"J Child Neurol"},{"key":"437_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/ana.21082","volume":"61","author":"L Vel\u00ed\u0161ek","year":"2007","unstructured":"Vel\u00ed\u0161ek L, Jehle K, Asche S, et al. Model of infantile spasms induced by N-methyl-D-aspartic acid in prenatally impaired brain. Ann Neurol. 2007;61:109\u201319.","journal-title":"Ann Neurol"},{"issue":"Suppl 3","key":"437_CR26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1528-1167.2010.02630.x","volume":"51","author":"L Vel\u00ed\u0161ek","year":"2010","unstructured":"Vel\u00ed\u0161ek L, Chachua T, Yum MS, et al. Model of cryptogenic infantile spasms after prenatal corticosteroid priming. Epilepsia. 2010;51(Suppl 3):145\u20139.","journal-title":"Epilepsia"},{"key":"437_CR27","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1111\/j.1528-1167.2011.03220.x","volume":"52","author":"T Chachua","year":"2011","unstructured":"Chachua T, Yum M-S, Vel\u00ed\u0161kov\u00e1 J, et al. Validation of the rat model of cryptogenic infantile spasms. Epilepsia. 2011;52:1666\u201377.","journal-title":"Epilepsia"},{"key":"437_CR28","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1016\/j.eplepsyres.2014.08.015","volume":"108","author":"MS Yum","year":"2014","unstructured":"Yum MS, Lee M, Ko TS, et al. A potential effect of ganaxolone in an animal model of infantile spasms. Epilepsy Res. 2014;108:1492\u2013500.","journal-title":"Epilepsy Res"},{"key":"437_CR29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.neuropharm.2011.02.018","volume":"61","author":"L Rambousek","year":"2011","unstructured":"Rambousek L, Buben\u00edkov\u00e1-Vale\u0161ov\u00e1 V, Ka\u010der P, et al. Cellular and behavioural effects of a new steroidal inhibitor of the N-methyl-d-aspartate receptor 3alpha5beta-pregnanolone glutamate. Neuropharmacology. 2011;61:61\u20138.","journal-title":"Neuropharmacology"},{"key":"437_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.neulet.2014.01.057","volume":"564","author":"L Klete\u010dkov\u00e1","year":"2014","unstructured":"Klete\u010dkov\u00e1 L, Tsenov G, Kubov\u00e1 H, et al. Neuroprotective effect of the 3alpha5beta-pregnanolone glutamate treatment in the model of focal cerebral ischemia in immature rats. Neurosci Lett. 2014;564:11\u20135.","journal-title":"Neurosci Lett"},{"key":"437_CR31","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3389\/fnbeh.2014.00130","volume":"8","author":"K Holubov\u00e1","year":"2014","unstructured":"Holubov\u00e1 K, Nekov\u00e1\u0159ov\u00e1 T, Pistov\u010d\u00e1kov\u00e1 J, et al. Pregnanolone glutamate, a novel use-dependent NMDA receptor inhibitor, exerts antidepressant-like properties in animal models. Front Behav Neurosci. 2014;8:130.","journal-title":"Front Behav Neurosci"},{"key":"437_CR32","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1476-5381.2011.01816.x","volume":"166","author":"J Borovsk\u00e1","year":"2012","unstructured":"Borovsk\u00e1 J, Vyklick\u00fd V, \u0160\u0165astn\u00e1 E, et al. Access of inhibitory neurosteroids to the NMDA receptor. Br J Pharmacol. 2012;166:1069\u201383.","journal-title":"Br J Pharmacol"},{"key":"437_CR33","doi-asserted-by":"publisher","first-page":"5950","DOI":"10.1021\/acs.jmedchem.5b00570","volume":"58","author":"E Kudov\u00e1","year":"2015","unstructured":"Kudov\u00e1 E, Chodounsk\u00e1 H, Slav\u00edkov\u00e1 B, et al. A new class of potent N-Methyl-D-Aspartate receptor inhibitors: sulfated neuroactive steroids with lipophilic D-Ring modifications. J Med Chem. 2015;58:5950\u201366.","journal-title":"J Med Chem"},{"key":"437_CR34","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1523\/JNEUROSCI.3181-15.2016","volume":"36","author":"V Vyklick\u00fd","year":"2016","unstructured":"Vyklick\u00fd V, \u0160mejkalov\u00e1 T, Krausov\u00e1 B, et al. Preferential inhibition of tonically over phasically activated NMDA receptors by pregnane derivatives. J Neurosci. 2016;36:2161\u201375.","journal-title":"J Neurosci"},{"key":"437_CR35","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1093\/toxsci\/kfs244","volume":"130","author":"Z Cao","year":"2012","unstructured":"Cao Z, Hammock BD, McCoy M, et al. Tetramethylenedisulfotetramine alters Ca2+ dynamics in cultured hippocampal neurons: mitigation by NMDA blockade and GABAA receptor positive modulation. Toxicol Sci. 2012;130:362\u201372.","journal-title":"Toxicol Sci"},{"key":"437_CR36","unstructured":"Kudov\u00e1 E, Chodounsk\u00e1 H, Mare\u0161 P, et al. 3alpha, 5beta-neuroactive steroids for the treatment of epilepsy and seizure diseases. US Patent Application Publication US20220162257A1, 26 May 2022."},{"key":"437_CR37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.eplepsyres.2019.03.004","volume":"152","author":"CR Chern","year":"2019","unstructured":"Chern CR, Chern CJ, Vel\u00ed\u0161kov\u00e1 J, et al. AQB-565 shows promise in preclinical testing in the model of epileptic spasms during infancy: head-to-head comparison with ACTH. Epilepsy Res. 2019;152:31\u20134.","journal-title":"Epilepsy Res"},{"key":"437_CR38","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3389\/fphar.2018.01299","volume":"9","author":"SK Adla","year":"2018","unstructured":"Adla SK, Slavikov\u00e1 B, Chodounsk\u00e1 H, et al. Strong inhibitory effect, low cytotoxicity and high plasma stability of steroidal inhibitors of N-Methyl-D-Aspartate receptors with C-3 amide structural motif. Front Pharmacol. 2018;9:1299.","journal-title":"Front Pharmacol"},{"key":"437_CR39","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/epi.13634","volume":"58","author":"M Bialer","year":"2017","unstructured":"Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs. A summary of the thirteenth Eilat conference on new antiepileptic drugs and devices (EILAT XIII). Epilepsia. 2017;58:181\u2013221.","journal-title":"Epilepsia"},{"key":"437_CR40","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s40265-022-01724-0","volume":"82","author":"YN Lamb","year":"2022","unstructured":"Lamb YN. Ganaxolone: first approval. Drugs. 2022;82:933\u201340.","journal-title":"Drugs"},{"key":"437_CR41","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.pediatrneurol.2019.11.008","volume":"107","author":"MS Perry","year":"2020","unstructured":"Perry MS. New and emerging medications for treatment of pediatric epilepsy. Pediatr Neurol. 2020;107:24\u20137.","journal-title":"Pediatr Neurol"},{"key":"437_CR42","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.neuint.2018.06.002","volume":"118","author":"JV Bukanova","year":"2018","unstructured":"Bukanova JV, Solntseva EI, Kolbaev SN, et al. Modulation of GABA and glycine receptors in rat pyramidal hippocampal neurones by 3alpha5beta-pregnanolone derivatives. Neurochem Int. 2018;118:145\u201351.","journal-title":"Neurochem Int"},{"key":"437_CR43","first-page":"977","volume":"46","author":"JE Hawkinson","year":"1994","unstructured":"Hawkinson JE, Kimbrough CL, Belelli D, et al. Correlation of neuroactive steroid modulation of [35S]t-butylbicyclophosphorothionate and [3H]flunitrazepam binding and gamma-aminobutyric acidA receptor function. Mol Pharmacol. 1994;46:977\u201385.","journal-title":"Mol Pharmacol"},{"key":"437_CR44","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.3390\/biom11071026","volume":"11","author":"K Holubova","year":"2021","unstructured":"Holubova K, Chvojkova M, Hrcka Krausova B, et al. Pitfalls of NMDA receptor modulation by neuroactive steroids. The effect of positive and negative modulation of NMDA receptors in an animal model of schizophrenia. Biomolecules. 2021;11:1026.","journal-title":"Biomolecules"},{"key":"437_CR45","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1126\/science.2422758","volume":"232","author":"MD Majewska","year":"1986","unstructured":"Majewska MD, Harrison NL, Schwartz RD, et al. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science. 1986;232:1004\u20137.","journal-title":"Science"},{"key":"437_CR46","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/0024-3205(86)90295-X","volume":"39","author":"LM Cole","year":"1986","unstructured":"Cole LM, Casida JE. Polychlorocycloalkane insecticide-induced convulsions in mice in relation to disruption of the GABA-regulated chloride ionophore. Life Sci. 1986;39:1855\u201362.","journal-title":"Life Sci"},{"key":"437_CR47","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1016\/0006-2952(74)90061-6","volume":"23","author":"C Schottler","year":"1974","unstructured":"Schottler C, Krisch K. Hydrolysis of steroid hormone esters by an unspecific carboxylesterase from pig liver microsomes. Biochem Pharmacol. 1974;23:2867\u201375.","journal-title":"Biochem Pharmacol"},{"key":"437_CR48","first-page":"995","volume":"40","author":"KW Gee","year":"1991","unstructured":"Gee KW, Lan NC. Gamma-aminobutyric acidA receptor complexes in rat frontal cortex and spinal cord show differential responses to steroid modulation. Mol Pharmacol. 1991;40:995\u20139.","journal-title":"Mol Pharmacol"},{"key":"437_CR49","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0028-3908(96)00066-4","volume":"35","author":"D Belelli","year":"1996","unstructured":"Belelli D, Lambert JJ, Peters JA, et al. Modulation of human recombinant GABAA receptors by pregnanediols. Neuropharmacology. 1996;35:1223\u201331.","journal-title":"Neuropharmacology"},{"key":"437_CR50","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1093\/bja\/aeh125","volume":"92","author":"CJ Weir","year":"2004","unstructured":"Weir CJ, Ling AT, Belelli D, et al. The interaction of anaesthetic steroids with recombinant glycine and GABAA receptors. Br J Anaesth. 2004;92:704\u201311.","journal-title":"Br J Anaesth"},{"key":"437_CR51","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s43440-020-00113-2","volume":"72","author":"P Mare\u0161","year":"2020","unstructured":"Mare\u0161 P, Kudov\u00e1 E, Vale\u0161 K, et al. Three neurosteroids as well as GABAergic drugs do not convert immediate postictal potentiation to depression in immature rats. Pharmacol Rep. 2020;72:1573\u20138.","journal-title":"Pharmacol Rep"},{"key":"437_CR52","doi-asserted-by":"publisher","first-page":"10935","DOI":"10.1038\/srep10935","volume":"5","author":"V Vyklick\u00fd","year":"2015","unstructured":"Vyklick\u00fd V, Krausov\u00e1 B, \u010cern\u00fd J, et al. Block of NMDA receptor channels by endogenous neurosteroids: implications for the agonist induced conformational states of the channel vestibule. Sci Rep. 2015;5:10935.","journal-title":"Sci Rep"},{"key":"437_CR53","first-page":"447","volume":"12","author":"F Hahn","year":"1960","unstructured":"Hahn F. Analeptics. Pharmacol Rev. 1960;12:447\u2013530.","journal-title":"Pharmacol Rev"},{"key":"437_CR54","doi-asserted-by":"publisher","first-page":"8607","DOI":"10.1073\/pnas.1407379111","volume":"111","author":"C Zhao","year":"2014","unstructured":"Zhao C, Hwang SH, Buchholz BA, et al. GABAA receptor target of tetramethylenedisulfotetramine. Proc Natl Acad Sci USA. 2014;111:8607\u201312.","journal-title":"Proc Natl Acad Sci USA"},{"key":"437_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.106950","volume":"105","author":"CR Chern","year":"2020","unstructured":"Chern CR, Chern CJ, Vel\u00ed\u0161kov\u00e1 J, et al. ACTON PROLONGATUM(R) suppresses spasms head to head with Acthar(R) Gel in the model of infantile spasms. Epilepsy Behav. 2020;105: 106950.","journal-title":"Epilepsy Behav"},{"key":"437_CR56","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/978-1-4684-5769-8_3","volume":"268","author":"R Dingledine","year":"1990","unstructured":"Dingledine R, Kleckner NW, McBain CJ. The glycine coagonist site of the NMDA receptor. Adv Exp Med Biol. 1990;268:17\u201326.","journal-title":"Adv Exp Med Biol"},{"key":"437_CR57","first-page":"259","volume-title":"Allosteric modulation of amino acid receptors: therapeutic implications","author":"JW Johnson","year":"1989","unstructured":"Johnson JW, Ascher P. Modulation of the NMDA response by glycine. In: Barnard EA, Costa E, editors. Allosteric modulation of amino acid receptors: therapeutic implications. New York: Raven; 1989. p. 259\u201364."},{"key":"437_CR58","unstructured":"Ko\u0161\u0165\u00e1lov\u00e1 T. \u00da\u010dinky neuroaktivn\u00edho steroidu na motoriku ml\u00e1\u010fat laboratorn\u00edho potkana [in Czech]; Effects of neuroactive steroid on motor behaviors in developing rats. Praha: Charles University, 2nd Faculty of Medicine; 2020."}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-022-00437-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-022-00437-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-022-00437-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T21:37:09Z","timestamp":1675287429000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-022-00437-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,23]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["437"],"URL":"https:\/\/doi.org\/10.1007\/s43440-022-00437-1","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,23]]},"assertion":[{"value":"5 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LV is a consultant for Angelini Pharma on topics unrelated to this project. Other co-authors have no conflicts to report besides the funding statement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}